Role of Glucagon in Automated Insulin Delivery

Leah M. Wilson, Peter G. Jacobs, Jessica R. Castle

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Treatment of type 1 diabetes with exogenous insulin often results in unpredictable daily glucose variability and hypoglycemia, which can be dangerous. Automated insulin delivery systems can improve glucose control while reducing burden for people with diabetes. One approach to improve treatment outcomes is to incorporate the counter-regulatory hormone glucagon into the automated delivery system to help prevent the hypoglycemia that can be induced by the slow pharmacodynamics of insulin action. This article explores the advantages and disadvantages of incorporating glucagon into dual-hormone automated hormone delivery systems.

Original languageEnglish (US)
Pages (from-to)179-202
Number of pages24
JournalEndocrinology and Metabolism Clinics of North America
Issue number1
StatePublished - Mar 2020


  • Dual-hormone artificial pancreas
  • Glucagon
  • Hypoglycemia
  • Intranasal glucagon
  • Minidose glucagon
  • Type 1 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Role of Glucagon in Automated Insulin Delivery'. Together they form a unique fingerprint.

Cite this